[go: up one dir, main page]

DK0706398T3 - Farmaceutisk sammensætning indeholdende heparin, heparinfragmenter eller derivater heraf i kombination med glycerolestere - Google Patents

Farmaceutisk sammensætning indeholdende heparin, heparinfragmenter eller derivater heraf i kombination med glycerolestere

Info

Publication number
DK0706398T3
DK0706398T3 DK94919936T DK94919936T DK0706398T3 DK 0706398 T3 DK0706398 T3 DK 0706398T3 DK 94919936 T DK94919936 T DK 94919936T DK 94919936 T DK94919936 T DK 94919936T DK 0706398 T3 DK0706398 T3 DK 0706398T3
Authority
DK
Denmark
Prior art keywords
heparin
pct
derivatives
combination
glycerol esters
Prior art date
Application number
DK94919936T
Other languages
English (en)
Inventor
Monica Einarsson
Original Assignee
Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Ab filed Critical Pharmacia Ab
Application granted granted Critical
Publication of DK0706398T3 publication Critical patent/DK0706398T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
DK94919936T 1993-06-18 1994-06-16 Farmaceutisk sammensætning indeholdende heparin, heparinfragmenter eller derivater heraf i kombination med glycerolestere DK0706398T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE19939302135A SE9302135D0 (sv) 1993-06-18 1993-06-18 New pharmaceutical composition
PCT/SE1994/000595 WO1995000152A1 (en) 1993-06-18 1994-06-16 Pharmaceutical composition containing heparin, heparin fragments or their derivatives in combination with glycerol esters

Publications (1)

Publication Number Publication Date
DK0706398T3 true DK0706398T3 (da) 2002-05-21

Family

ID=20390356

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94919936T DK0706398T3 (da) 1993-06-18 1994-06-16 Farmaceutisk sammensætning indeholdende heparin, heparinfragmenter eller derivater heraf i kombination med glycerolestere

Country Status (10)

Country Link
US (1) US5714477A (da)
EP (1) EP0706398B1 (da)
JP (1) JP3953510B2 (da)
AT (1) ATE209038T1 (da)
DE (1) DE69429169T2 (da)
DK (1) DK0706398T3 (da)
ES (1) ES2168299T3 (da)
PT (1) PT706398E (da)
SE (1) SE9302135D0 (da)
WO (1) WO1995000152A1 (da)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6008228A (en) * 1995-06-06 1999-12-28 Hoffman-La Roche Inc. Pharmaceutical compositions containing proteinase inhibitors
SE9602145D0 (sv) * 1996-05-31 1996-05-31 Astra Ab New improved formulation for treatment of thromboembolism
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
US8119159B2 (en) * 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US20070148228A1 (en) * 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
US6761903B2 (en) 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6982281B1 (en) * 2000-11-17 2006-01-03 Lipocine Inc Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US6458383B2 (en) 1999-08-17 2002-10-01 Lipocine, Inc. Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin
US20030236236A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
JP2003504428A (ja) * 1999-06-30 2003-02-04 ハミルトン シビック ホスピタルズ リサーチ ディベロップメント インコーポレイテッド クロット関連凝固因子を阻害するヘパリン組成物
WO2001056594A1 (en) 2000-02-04 2001-08-09 Unigene Laboratories, Inc. Nasal calcitonin formulations
DE10026699A1 (de) * 2000-05-30 2001-12-06 Basf Ag Formulierung auf Heparin-, Glycosaminoglycan- oder Heparinoidbasis und Verwendung der Formulierung sowie der Formulierungsgrundlage
WO2002020091A2 (en) * 2000-09-08 2002-03-14 Hamilton Civic Hospitals Research Development Inc. Antithrombotic compositions
CA2446622C (en) * 2001-05-11 2012-08-14 Elan Corporation, Plc Isostearic acid salts as permeation enhancers
WO2002092616A1 (en) * 2001-05-11 2002-11-21 Orasense, Ltd. Antisense permeation enhancers
ATE454137T1 (de) * 2001-07-25 2010-01-15 Facet Biotech Corp Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab
SE521676C2 (sv) * 2002-01-02 2003-11-25 Dilafor Ab Användning av glykosaminoglykaner för prevention och behandling av värksvaghet vid fullgången graviditet
US20040072796A1 (en) * 2002-04-18 2004-04-15 Embury Stephen H. Method and composition for preventing pain in sickle cell patients
US20060003002A1 (en) * 2003-11-03 2006-01-05 Lipocine, Inc. Pharmaceutical compositions with synchronized solubilizer release
US20070219131A1 (en) * 2004-04-15 2007-09-20 Ben-Sasson Shmuel A Compositions capable of facilitating penetration across a biological barrier
US20050232981A1 (en) * 2004-04-15 2005-10-20 Ben-Sasson Shmuel A Compositions capable of facilitating penetration across a biological barrier
EP1750729A2 (en) * 2004-05-06 2007-02-14 Emisphere Technologies, Inc. Solid dosage form of wetted heparin
CA2565188C (en) 2004-05-14 2014-03-04 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US20050282775A1 (en) * 2004-06-16 2005-12-22 Paringenix, Inc. Method and medicament for sulfated polysaccharide treatment of inflammation without inducing platelet activation and heparin-induced thrombocytopenia syndrome
US7563780B1 (en) * 2004-06-18 2009-07-21 Advanced Cardiovascular Systems, Inc. Heparin prodrugs and drug delivery stents formed therefrom
ZA200801696B (en) * 2005-07-22 2009-08-26 Univ California Heparin compositions and selection inhibition
US20070154546A1 (en) * 2005-12-30 2007-07-05 Zhang Jack Y Sustained release pharmaceutical compositions
BRPI0710503A2 (pt) * 2006-04-07 2011-08-16 Merrion Res Iii Ltd uso de uma composição farmacêutica, composição farmacêutica, e, forma de dosagem oral
EP2040731A4 (en) * 2006-06-09 2010-05-19 Merrion Res Iii Ltd SOLID DOSAGE FORM FOR ORAL ADMINISTRATION CONTAINING AN ACTIVATOR
US20090280169A1 (en) * 2008-05-07 2009-11-12 Merrion Research Iii Limited Compositions of peptides and processes of preparation thereof
HRP20170929T1 (hr) 2008-09-17 2017-09-22 Chiasma Inc. Farmaceutski pripravci i odgovarajući postupci za isporuku
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
TWI480286B (zh) * 2009-02-25 2015-04-11 Merrion Res Iii Ltd 雙膦酸鹽類組合物及藥物遞送
WO2011084618A2 (en) 2009-12-16 2011-07-14 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
US20110142889A1 (en) * 2009-12-16 2011-06-16 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
EP2512448B1 (en) 2009-12-18 2016-07-06 Endotis Pharma Pharmaceutical oral dosage form containing a synthetic oligosaccharide
US20110182985A1 (en) * 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
WO2011120033A1 (en) * 2010-03-26 2011-09-29 Merrion Research Iii Limited Pharmaceutical compositions of selective factor xa inhibitors for oral administration
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
AU2012204213A1 (en) 2011-01-07 2013-06-13 Merrion Research Iii Limited Pharmaceutical compositions of iron for oral administration
LT2846809T (lt) 2012-05-09 2021-01-25 Cantex Pharmaceuticals, Inc. Mielosupresijos gydymas
WO2016033556A1 (en) 2014-08-28 2016-03-03 Lipocine Inc. BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
JP7211704B2 (ja) 2015-01-29 2023-01-24 ノヴォ ノルディスク アー／エス Ｇｌｐ－１アゴニスト及び腸溶コーティングを含む錠剤
AU2016215350B2 (en) 2015-02-03 2021-11-25 Amryt Endo, Inc. Method of treating diseases
US10052346B2 (en) 2015-02-17 2018-08-21 Cantex Pharmaceuticals, Inc. Treatment of myelodysplastic syndromes with 2-O and,or 3-O desulfated heparinoids
US20160361322A1 (en) 2015-06-15 2016-12-15 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
US20180147215A1 (en) 2016-11-28 2018-05-31 Lipocine Inc. Oral testosterone undecanoate therapy
AU2019308326B2 (en) 2018-07-20 2025-07-31 Lipocine Inc. Liver disease
CA3117606A1 (en) * 2018-10-25 2020-04-30 Zeenar Enterprises Pty Ltd Composition that forms liquid crystalline particles
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3510561A (en) * 1965-05-20 1970-05-05 Canada Packers Ltd Sulfone-enhanced heparin absorption through mucous membranes
JPS53107408A (en) * 1977-02-28 1978-09-19 Yamanouchi Pharmaceut Co Ltd Micellar preparation for rectal infusion
CA1136620A (en) * 1979-01-08 1982-11-30 Ulf P.F. Lindahl Heparin fragments having selective anticoagulation activity
EP0037943B1 (en) * 1980-03-31 1985-08-14 Teijin Limited Pharmaceutical composition for intrarectal administration, and suppository prepared therefrom
JPS6028972A (ja) * 1983-06-29 1985-02-14 Kyowa Hakko Kogyo Co Ltd ジベンゾ［ｂ，ｅ］オキセピン誘導体
DE3331009A1 (de) * 1983-08-27 1985-03-14 Basf Ag, 6700 Ludwigshafen Verfahren zur erhoehung der enteralen resorbierbarkeit von heparin bzw. heparinoiden sowie das so erhaeltliche heparin- bzw. heparinoidpraeparat
FR2616661B1 (fr) * 1987-06-19 1991-06-07 Doutremepuich Christian Composition a base de mucopolysaccharides hepariniques, active par voie orale
DE3805523A1 (de) * 1988-02-22 1989-10-05 Schur Pharmazeutika Gmbh & Co Pharmazeutische praeparate zur transdermalen applikation von heparin

Also Published As

Publication number Publication date
JP3953510B2 (ja) 2007-08-08
ATE209038T1 (de) 2001-12-15
DE69429169T2 (de) 2002-06-20
EP0706398A1 (en) 1996-04-17
ES2168299T3 (es) 2002-06-16
US5714477A (en) 1998-02-03
WO1995000152A1 (en) 1995-01-05
PT706398E (pt) 2002-05-31
JPH09501652A (ja) 1997-02-18
DE69429169D1 (de) 2002-01-03
SE9302135D0 (sv) 1993-06-18
EP0706398B1 (en) 2001-11-21

Similar Documents

Publication Publication Date Title
DK0706398T3 (da) Farmaceutisk sammensætning indeholdende heparin, heparinfragmenter eller derivater heraf i kombination med glycerolestere
DK0746317T3 (da) Sublingual eller bukkal farmaceutisk sammensætning
EP1153924A3 (en) Substituted 1,3-oxathiolanes with antiviral properties
TR200001982T2 (tr) Farmasötik vurulu salınımlı oral dozaj şekli.
IT1288290B1 (it) Acido ialuronico autoreticolato e relative composizioni farmaceutiche per il trattamento delle artropatie
BR9810450A (pt) Derivados de ácido barbitúrico com atividade antimetastática e antitumor
AU4884696A (en) Pharmaceutical compositions comprising monoamine oxidase B inhibitors
DE69713300D1 (de) Benzopyran derivate mit leukotrien-antagonistischer wirkung
DE69217554D1 (de) Ebastin oder ebastin-analoga enthaltende arzneimittel
ATE165827T1 (de) Herstellung von n-acetylneuraminsäure-derivaten
GR3034821T3 (en) New 6-hydroxy and 6-oxo-anstro-stane derivatives active on the cardiovascular system and pharmaceutical compositions containing same
TR200000153T2 (tr) İl-5 inhibite eden 6-azaurasil türevleri.
DK0937060T3 (da) Nye cis-3,4-chroman-derivater, der er nyttige i forebyggelsen eller behandlingen af østrogen-relaterede sygdomme eller syndromer
ATE237614T1 (de) Benzo(c)chinolizin derivate,deren herstellung und verwendung als 5-alfa-reduktase inhibitoren
ATE59295T1 (de) Prazosin-pirbuterol-mischung zur bronchendilatation.
FI951277A0 (fi) Uudet N,N,N',N'-tetrasubstituoituneet 1,2-etaanidiamiinijohdannaisyhdisteet
DK0937057T3 (da) Hidtil ukendte (-)-enantiomerer af cis-3,4-chromanderivater anvendelige i forebyggelse eller behandling af østrogenrelaterede sygdomme eller syndromer
DK0937062T3 (da) Nye cis-3,4-chroman-derivater, der er nyttige i forebyggelsen eller behandlingen af østrogen-relaterede sygdomme eller syndromer
CA2434775A1 (en) Compounds for use in the treatment of skin conditions
DE69931504D1 (de) Zusammensetzungen zur linderung der nebeneffekte des interleukin-2
SE8303031D0 (sv) Improved steroid esters preparation
DE59304476D1 (de) Lagerstabile Lösungen von carbonisiertem Magnesiumethylat in Ethanol sowie deren Herstellung und Verwendung
AU6878900A (en) 1,4-dihydropyridine-5-carboxylic acid ester derivatives and method for the preparation thereof
ES2145541T3 (es) Nuevos seco-d-esteroides activos sobre el sistema cardiovascular, procedimientos para su preparacion y composiciones farmaceuticas que los contienen.
ES2069500B1 (es) Perfeccionamientos introducidos en el objeto de la patente espa¦ola n 9201983 por "procedimiento para la obtencion de benzoxazinas utiles para la sintesis de oflexacina, levofloxacina y derivados.